Novacyt

Novacyt Fixed Asset Turnover

The Fixed Asset Turnover of Novacyt (ALNOV.PA) as of Oct 18, 2026 is 1.83. In the previous year, Fixed Asset Turnover was 0.76 — a change of 141.11% (higher).

Fixed Asset Turnover

1.83

YoY

141.11%

Last updated:

Fixed Asset Turnover of Novacyt is 2024 1.83 . Fixed Asset Turnover of Novacyt was 2023 0.76 . It decreases by 141.11% higher compared to the previous year.

The Novacyt Fixed Asset Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Fixed Asset Turnover
Date
Fixed Asset Turnover
Jan 1, 2017
8.10 GBP
Jan 1, 2018
11.52 GBP
Jan 1, 2019
3.76 GBP
Jan 1, 2020
71.04 GBP
Jan 1, 2021
14.51 GBP
Jan 1, 2022
6.43 GBP
Jan 1, 2023
0.76 GBP
Jan 1, 2024
1.83 GBP
The Novacyt Fixed Asset Turnover history
YEARFixed Asset TurnoverYoY
1.83+141.11%
0.76-88.17%
6.43-55.68%
14.51-79.58%
71.04+1,790.25%
3.76-67.38%
11.52+42.14%
8.10-19.74%
10.10-22.34%
13.00+53.12%
8.49—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Fixed Asset Turnover of Novacyt is 1.83 in 2024.

Fixed Asset Turnover of Novacyt changed from 0.76 to 1.83, representing a 141.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Fixed Asset Turnover Novacyt since 2006 – with annual values, charts, and detailed analysis.

Fixed asset turnover measures revenue generated per unit of PP&E. Higher ratios indicate more efficient utilization of physical assets.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Fixed Asset Turnover's Novacyt with sector peers and the industry average to assess whether it is attractive.

To evaluate Fixed Asset Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Fixed Asset Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Novacyt

All Key Metrics — Novacyt